Internal Medicine, Hematology & Oncology · Lisle, IL
NPI
1437194610
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
430 Warrenville Rd, 300
Lisle, IL, 60532
Phone (630) 364-7850
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.2M
387,093 services
Medicare patients, 2024
1,403
Average age 75
Drug cost, 2024
$8.5M
2,978 prescriptions
Company payments, 2025
$137
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Daniel J Frank was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 46,410 times for 43 patients. In total Daniel J Frank billed 387,093 services in 214 codes, and Medicare paid $7.2M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-08-08.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 46,410 | 43 | $0.27 | $12K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 30,800 | 31 | $44.49 | $1.4M |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 25,000 | 17 | $2.32 | $58K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 22,500 | 21 | $39.33 | $885K |
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 16,200 | 20 | $17.17 | $278K |
| J0897 Injection, denosumab, 1 mg | Office | 16,020 | 41 | $20.71 | $332K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 15,450 | 41 | $0.11 | $1,676 |
| J9267 Injection, paclitaxel, 1 mg | Office | 12,498 | 14 | $0.08 | $1,020 |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 11,525 | 35 | $33.82 | $390K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,030 | 28 | $24.79 | $100K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 3,574 | 17 | $0.23 | $813 |
| 36415 Venipuncture Blood Collection | Office | 2,474 | 704 | $8.65 | $21K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,272 | 49 | $0.09 | $207 |
| 85025 Blood Count | Office | 2,182 | 667 | $7.61 | $17K |
| 80053 Clinical Chemistry | Office | 1,949 | 607 | $10.35 | $20K |
By year: 2022 $7.2M for 370,957 services; 2023 $6.1M for 361,820 services; 2024 $7.2M for 387,093 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 2,474 | 704 | $8.65 | $21K |
| 85025 Blood Count | 2,182 | 667 | $7.61 | $17K |
| 80053 Clinical Chemistry | 1,949 | 607 | $10.35 | $20K |
| 83615 Clinical Chemistry | 408 | 224 | $5.92 | $2,415 |
| 82728 Clinical Chemistry | 214 | 126 | $13.36 | $2,859 |
| 83540 Clinical Chemistry | 203 | 120 | $6.34 | $1,287 |
| 83550 Clinical Chemistry | 203 | 120 | $8.57 | $1,740 |
| 83735 Clinical Chemistry | 189 | 41 | $6.57 | $1,242 |
| 85027 Blood Count | 184 | 62 | $6.34 | $1,167 |
| 85007 Blood Count | 179 | 62 | $3.72 | $666 |
Medicare prescription drug claims, 2024
In 2024, the drug Daniel J Frank prescribed most often to Medicare patients was Anastrozole, with 469 prescriptions and refills. In total Daniel J Frank wrote 2,978 Medicare prescriptions that cost $8.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 469 | 1,364 | 182 | $9,845 |
| Eliquis Apixaban | 168 | 347 | 57 | $198K |
| Tamoxifen Citrate Generic | 159 | 463 | 68 | $4,963 |
| Prednisone Generic | 156 | 339 | 72 | $1,386 |
| Dexamethasone Generic | 137 | 152 | 77 | $2,244 |
| Xarelto Rivaroxaban | 115 | 210 | 36 | $111K |
| Letrozole Generic | 101 | 276 | 34 | $2,043 |
| Prochlorperazine Maleate Generic | 89 | 89 | 73 | $686 |
| Abiraterone Acetate Generic | 81 | 151 | 19 | $21K |
| Gabapentin Generic | 76 | 174 | 32 | $1,237 |
| Ondansetron Hcl Generic | 69 | 71 | 55 | $314 |
| Imbruvica Ibrutinib | 67 | 76 | 11 | $1.2M |
| Acyclovir Generic | 65 | 141 | 21 | $1,308 |
| Ibrance Palbociclib | 59 | 59 | Under 11 | $923K |
| Warfarin Sodium Generic | 59 | 166 | 20 | $483 |
Brand drugs: 785 claims; generic drugs: 2,193 claims; opioid claims: 121.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Daniel J Frank $137 ($137 in general payments such as food, travel and fees) from 4 companies. The largest payer was Gilead Sciences, Inc. with $80.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.